Spreading depolarisations following severe traumatic brain injury are associated with a poor outcome. They serve to cause secondary injury and energy imbalance. This mechanism might provide a target for therapeutic intervention.
Based on a retrospective study of 34 patients, the authors report that clinical manifestations of brain involvement are not uncommon in the neuromyelitis optica spectrum of disorders.
New indication for rivaroxaban; new study on warfarin testing; medications causing adverse drug events; niacin as an add-on therapy; and FDA actions.
Dihydroergotamine, in a longer 5-day intravenous protocol for refractory primary headache appears to be efficacious, but this older medication needs to be compared directly to newer migraine treatments.
